| Back to the HDR 2006 programme >> | ||||
![]() |
Session 1: Protein Kinases as Drug targets Chair: Prof. Raimo K. Tuominen, University of Helsinki Lectures and Oral Communications in Red are from members of our Consortium. |
|||
|
||||
| The Visualization of Anchored Kinase Signaling Events Dr. John D. Scott, Oregon Health and Science University, USA |
||||
| Regulatory Domains of PKC as Drug Targets Dr. Victor Marquez, NCI, NIH, USA |
||||
| A Staurosporine Story: Indolocarbazole Orthoamides and Fluorinated Analogs of
LY333531 Prof. Peter Goekjian, CNRS Lyon, France |
||||
ATP-Binding Site of Protein Kinases Dr. Doriano Fabbro, Novartis, Switzerland |
||||
Protein kinases play an essential role in many
signaling pathways and have the potential to contribute to diseases ranging from
cancer and inflammation to diabetes, cardiovascular as well as other disorders.
Therefore protein kinases have become one of the most populated class of
druggable targets. Identification of kinase specificity and functional
validation of kinase as targets has been a challenge, but innovative approaches
have been developed to address these issues and over the years a few lessons
have been learned: |
||||
|
![]() |
|||
| Dr. Doriano Fabbro | ||||
2. Kinases can escape inhibition by mutating
key residues in their catalytic domain and thus become resistant to the
kinase inhibitors. |
||||
| The Visualization of Anchored Kinase Signaling Events John D. Scott Oregon Health and Science University, USA |
||||
Multiprotein signaling networks create focal points of enzyme activity that disseminate the intracellular action of many hormones and neurotransmitters. Accordingly, the spatio-temporal activation of protein kinases and phosphatases is an important factor in controlling where and when phosphorylation events occur. Anchoring proteins provide a molecular framework that orients these enzymes towards selected substrates. A-kinase anchoring proteins (AKAPs) are signal-organizing molecules that compartmentalize the cAMP dependent protein kinase, phosphodiesterases and a variety of enzymes that are regulated by second messengers. Using a combination of live cell imaging, biochemical, genetic and electrophysiological techniques I will discuss two emerging principles in AKAP signaling: the combinatorial assembly of different enzymes on the same AKAP backbone; and the dynamic reorganization of AKAP complexes. |
![]() John D. Scott |
|||
| Regulatory Domains of PKC as Drug Targets Dr. Victor Marquez, NCI, NIH, USA |
||||
![]() |
The weak binding affinity of DAG for the C1 domains of PKC’s and the
complicated structures and restricted supply of natural product ligands
prompted us to devise a strategy to enhance the affinity of DAG by means of
an optimized DAG-lactone template. DAG-lactones have been designed to
selectively direct the flow of information from the DAG signaling pathways
through its multiple signal transducers that contain DAG-responsive C1
domains. |
|||
| Dr. Victor Marquez | Because the substrates for PKC phosphorylation and their roles in downstream events are poorly understood, our efforts have been directed to the head of these pathways, at the level of DAG-C1 domain interactions. Since the actual DAG binding site represents a complex of lipid bilayer and C1 domain, for which the C1 domain represents only a half-site, the interactions with the phospholipid head groups are important albeit difficult to predict. We surmised that the specific cellular localization and response of an activated isozyme ought to be determined in part by the different lipid composition of the membranes, and the targeting information intrinsic to the individual isoform. Because structure-activity analyses incorporating the lipid bilayer are still rudimentary, we have decided to explore this aspect indirectly. Thus, we have implemented the syntheses of combinatorial libraries where randomly chosen groups decorating the DAG-lactones generate a series of chemical “zip codes” that create a different PKC-lipid microenvironment capable of directing the activated complex to different sub-cellular sites. Our preliminary results provide a strong proof-of-principle for the concept of chemical “zip codes” which form the basis for new therapeutic strategies selectively targeting these pathways. |
|||
|
||||
| A Staurosporine Story: Indolocarbazole Orthoamides and Fluorinated Analogs of
LY333531 Prof. Peter Goekjian, CNRS Lyon, France Anne Jochum1, Thierry Lamouille1, Stein Døskeland2, Peter Parker & Peter Goekjian1,3 1 Universite Claude Bernard-Lyon 1, UMR 5181, Villeurbanne, France 2 University of Bergen, Bergen, Norway 3 CR-UK London Research Institute, London, UK |
||||
|
Staurosporine, initially identified as a protein kinase C inhibitor, has
turned out to be a highly promiscuous inhibitor. It has inspired a
remarkable array of novel compounds, and many highly selective compounds
have been found based on this lead structure. We will describe a few aspects
of our own foray in this area, in particular with respect to fluoro analogs
of LY333531 (ruboxistaurin) and orthoamide analogs of rebeccamycin. |
|||
| Prof. Peter Goekjian | Previous results in our laboratories suggested that two conformations
dominate in the 14-membered ring macrocyclic bis(indolyl)maleimides. We
believe that placing a fluorine atom at the 4-position of one of the indole
rings of LY333531 would create an unfavorable lone-pair/lone pair
interaction with the carbonyl, and favor a conformation in which the
4-fluorindole ring is perpendicular to the maleimide ring. Indole-fluorinated
macrocyclic bisindolylmaleimide have been synthesized to test the hypothesis
that this conformation is responsible for the selectivity of LY333531 for
the beta isoform of PKC. |
|||
Back to the HDR 2006 programme >> |
||||




